<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04346992</url>
  </required_header>
  <id_info>
    <org_study_id>R109</org_study_id>
    <nct_id>NCT04346992</nct_id>
  </id_info>
  <brief_title>Prevalence Of Keratoconus Among Patients With Thyroid Gland Dysfunction</brief_title>
  <official_title>Prevalence Of Keratoconus Among Patients With Thyroid Gland Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fayoum University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fayoum University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hormonal imbalances are likely to affect the corneal metabolism and may be also associated
      with Keratoconus. Among the various endocrinologic dysfunctions assumed so far, thyroid gland
      dysfunction (TGD) (hypo- or hyperthyroidism; comprised as TGD) is frequently associated with
      eye diseases such as Graves disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim of the work

      We aim to examine the prevalence of KC among patients already diagnosed by endocrinologist
      with TGD.

      Materials and methods

      Our Screening for KC will include evaluation of the demographic data and complete
      ophthalmological examination of the patients using:

      VA Refraction K reading Slit lamp examination Pentacam Study design Epidemiological study

      Inclusion citeria All patients diagnosed as thyroid gland dysfunction Control group

      Exclusion criteria Uncooperative patients
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2020</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>prevalence of keratoconus in thyroid gland dysfunction</measure>
    <time_frame>we will recruit patients who meer the inclusion criteria during the study period April-August 2020</time_frame>
    <description>Our Screening for KC will include evaluation of the demographic data and complete ophthalmological examination of the patients using:
VA Refraction K reading Slit lamp examination Pentacam</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Keratoconus in Thyroid Gland Dysfunction</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>no intervention</description>
  </intervention>
  <biospec_descr>
    <textblock>
      blood sample to measure thyroid profile
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        we will enroll all patients who meet the inclusion criteria and signed a written informed
        consent form
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients diagnosed as thyroid gland dysfunction

        Exclusion Criteria:

          -  Uncooperative patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Omar Said, MD</last_name>
    <phone>00201003508051</phone>
    <email>oms01@fayoum.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fayoum University</name>
      <address>
        <city>Fayoum</city>
        <zip>63514</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omar Said, MD</last_name>
      <phone>00201003508051</phone>
      <email>oms01@fayoum.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 12, 2020</study_first_submitted>
  <study_first_submitted_qc>April 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>April 12, 2020</last_update_submitted>
  <last_update_submitted_qc>April 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fayoum University</investigator_affiliation>
    <investigator_full_name>Omar Said</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

